G. Rigatos

702 total citations
35 papers, 553 citations indexed

About

G. Rigatos is a scholar working on Oncology, Dermatology and Cancer Research. According to data from OpenAlex, G. Rigatos has authored 35 papers receiving a total of 553 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 11 papers in Dermatology and 9 papers in Cancer Research. Recurrent topics in G. Rigatos's work include Cancer Treatment and Pharmacology (21 papers), Breast Cancer Treatment Studies (7 papers) and HER2/EGFR in Cancer Research (7 papers). G. Rigatos is often cited by papers focused on Cancer Treatment and Pharmacology (21 papers), Breast Cancer Treatment Studies (7 papers) and HER2/EGFR in Cancer Research (7 papers). G. Rigatos collaborates with scholars based in Greece, United States and United Kingdom. G. Rigatos's co-authors include Alexandros Ardavanis, A. Alexopoulos, Dimitrios Tryfonopoulos, George Ioannidis, George Orphanos, Nikolaos Malamos, K. Kalbakis, Sofia Agelaki, Anna Potamianou and S. Kakolyris and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of the New York Academy of Sciences.

In The Last Decade

G. Rigatos

35 papers receiving 528 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
G. Rigatos Greece 12 364 138 115 114 75 35 553
T. Habeshaw United Kingdom 13 294 0.8× 78 0.6× 34 0.3× 139 1.2× 84 1.1× 28 516
T. Giannakakis Greece 13 367 1.0× 121 0.9× 56 0.5× 68 0.6× 79 1.1× 24 457
Anna Potamianou Greece 13 481 1.3× 198 1.4× 54 0.5× 66 0.6× 118 1.6× 37 716
E. Pasquini Italy 13 253 0.7× 90 0.7× 27 0.2× 85 0.7× 52 0.7× 35 470
Jean Pierre Delord France 13 514 1.4× 57 0.4× 110 1.0× 87 0.8× 233 3.1× 20 792
Meltem Baykara Türkiye 12 153 0.4× 41 0.3× 53 0.5× 76 0.7× 51 0.7× 48 349
Concepción Fernández‐Chacón Spain 5 252 0.7× 108 0.8× 28 0.2× 61 0.5× 76 1.0× 6 374
F. Asrari United States 10 401 1.1× 269 1.9× 90 0.8× 173 1.5× 29 0.4× 23 847
Maria K. Beykirch Germany 7 345 0.9× 97 0.7× 33 0.3× 48 0.4× 127 1.7× 11 554
Aliki Taylor United Kingdom 11 385 1.1× 112 0.8× 17 0.1× 105 0.9× 133 1.8× 17 613

Countries citing papers authored by G. Rigatos

Since Specialization
Citations

This map shows the geographic impact of G. Rigatos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G. Rigatos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G. Rigatos more than expected).

Fields of papers citing papers by G. Rigatos

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by G. Rigatos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G. Rigatos. The network helps show where G. Rigatos may publish in the future.

Co-authorship network of co-authors of G. Rigatos

This figure shows the co-authorship network connecting the top 25 collaborators of G. Rigatos. A scholar is included among the top collaborators of G. Rigatos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with G. Rigatos. G. Rigatos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Orphanos, George, et al.. (2009). A Phase II trial of the combination of vinorelbine and capecitabine as second-line treatment in metastatic breast cancer previously treated with taxanes and/or anthracyclines. Journal of Cancer Research and Clinical Oncology. 136(1). 115–121. 7 indexed citations
2.
Ardavanis, Alexandros, et al.. (2009). Bevacizumab (BEV) and paclitaxel (PAC) every two weeks as first-line treatment for advanced breast cancer (ABC). Preliminary results.. Cancer Research. 69(2_Supplement). 4121–4121. 1 indexed citations
3.
Kountourakis, Panteleimon, et al.. (2008). Bevacizumab added to the irinotecan and capecitabine combination for advanced colorectal cancer. Journal of Clinical Oncology. 26(15_suppl). 15085–15085. 1 indexed citations
4.
Ardavanis, Alexandros, et al.. (2007). Trastuzumab with taxanes in HER2-ECD(+), IHC/CISH(-) advanced and heavily pretreated, chemotherapy-refractory breast cancer patients: Findings from a case series. Journal of Clinical Oncology. 25(18_suppl). 1089–1089. 1 indexed citations
5.
Ioannidis, George, et al.. (2007). Quality of life in metastatic breast cancer patients under chemotherapy or supportive care: a single-institution comparative study. European Journal of Cancer Care. 16(5). 433–438. 28 indexed citations
6.
Karamouzis, Michalis V., et al.. (2006). A case of HER-2(+) squamous cell breast carcinoma: An unusual presentation of an unusual clinical entity. European Journal of Surgical Oncology. 32(10). 1250–1251. 13 indexed citations
7.
Ardavanis, Alexandros, et al.. (2005). Safety and Efficacy of Trastuzumab Every 3 Weeks Combined with Cytotoxic Chemotherapy in Patients with HER2-Positive Recurrent Breast Cancer: Findings from a Case Series. Oncology Research and Treatment. 28(11). 558–564. 5 indexed citations
8.
Alexopoulos, A., et al.. (2005). Multiple cutaneous acral metastases in a woman with breast adenocarcinoma treated with pegylated liposomal doxorubicin: incidental or aetiological association?. European Journal of Cancer Care. 14(3). 267–271. 6 indexed citations
9.
Ardavanis, Alexandros, et al.. (2005). Gemcitabine and docetaxel as first-line treatment for advanced urothelial carcinoma: a phase II study. British Journal of Cancer. 92(4). 645–650. 50 indexed citations
10.
Alexopoulos, A., et al.. (2004). Phase II study of pegylated liposomal doxorubicin (Caelyx®) and docetaxel as first-line treatment in metastatic breast cancer. Annals of Oncology. 15(6). 891–895. 41 indexed citations
11.
Alexopoulos, A., et al.. (2004). In vivo synergism between docetaxel and gemcitabine in patients with metastatic breast cancer: General concepts and future perspectives. Seminars in Oncology. 31(2 Suppl 5). 25–30. 5 indexed citations
12.
Tryfonopoulos, Dimitrios, et al.. (2004). Non-allergic nature of docetaxel-induced acute hypersensitivity reactions. Anti-Cancer Drugs. 15(6). 581–585. 47 indexed citations
13.
Alexopoulos, A., et al.. (2003). Evidence for in vivo synergism between docetaxel and gemcitabine in patients with metastatic breast cancer. Annals of Oncology. 15(1). 95–99. 40 indexed citations
14.
Alexopoulos, A., Ch. Kouroussis, Nikolaos Malamos, et al.. (2001). Docetaxel in combination with mitoxantrone and granulocyte colony-stimulating factor as front-line chemotherapy in metastatic breast cancer: A multicenter phase II study. Annals of Oncology. 12(6). 793–798. 4 indexed citations
15.
Mavroudis, Dimitriοs, A. Alexopoulos, Nikolaos Ziras, et al.. (2000). Front-line treatment of advanced breast cancer with docetaxel and epirubicin: A multicenter phase II study. Annals of Oncology. 11(10). 1249–1254. 27 indexed citations
16.
Alexopoulos, C.G., et al.. (1999). A phase II study of the effectiveness of docetaxel (Taxotere) in women with advanced breast cancer previously treated with polychemotherapy. Cancer Chemotherapy and Pharmacology. 44(3). 253–258. 12 indexed citations
17.
Mavroudis, Dimitriοs, Nikolaos Malamos, A. Alexopoulos, et al.. (1999). Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: A multicenter phase II trial. Annals of Oncology. 10(2). 211–216. 86 indexed citations
18.
Alexopoulos, Athanasios, et al.. (1997). Subcutaneous nodules as initial metastatic sites in osteosarcoma. International Journal of Dermatology. 36(8). 606–609. 7 indexed citations
19.
Rigatos, G.. (1997). Cancer and Truth‐telling in Greece. Annals of the New York Academy of Sciences. 809(1). 382–392. 11 indexed citations
20.
Petridou, Eleni, Nick Dessypris, Gerasimos Aravantinos, et al.. (1997). Baldness and other correlates of sex hormones in relation to testicular cancer. International Journal of Cancer. 71(6). 982–985. 58 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by T. Habeshaw Breakdown of academic impact, for papers by T. Giannakakis Breakdown of academic impact, for papers by Anna Potamianou Breakdown of academic impact, for papers by E. Pasquini Breakdown of academic impact, for papers by Jean Pierre Delord Breakdown of academic impact, for papers by Meltem Baykara Breakdown of academic impact, for papers by Concepción Fernández‐Chacón Breakdown of academic impact, for papers by F. Asrari Breakdown of academic impact, for papers by Maria K. Beykirch Breakdown of academic impact, for papers by Aliki Taylor
Rankless by CCL
2026